Limits...
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.

Lafeuillade A, Soriano V, Suzan-Monti M, Stevenson M, Izopet J, Stellbrink HJ - AIDS Res Ther (2012)

Bottom Line: However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted.Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual.The main 2012 ISHEID theme was, hence "searching for an HIV cure".

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Infectious Diseases, General Hospital, Toulon, France. alain.lafeuillade@ch-toulon.fr.

ABSTRACT
The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence "searching for an HIV cure". In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.

No MeSH data available.


Related in: MedlinePlus

Treatment of chronic hepatitis C withBoceprevir in HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin, SVR12: sustained virological response at 12 weeks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472320&req=5

Figure 2: Treatment of chronic hepatitis C withBoceprevir in HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin, SVR12: sustained virological response at 12 weeks.

Mentions: The results so far available with boceprevir and telaprevir in HIV/HCV-coinfected patients were deeply discussed at ISHEID [41]. In the phase 2 boceprevir study, a total of 98 HCV genotype 1 patients were randomized to receive either triple therapy or standard of care (peginterferon-ribavirin) for one year. Two thirds of patients were infected with HCV subtype 1a. Seven patients experienced viral breakthrough during therapy, 3/64 in the boceprevir arm and 4/34 in the control arm. Severe anemia developed in 5% of patients assigned to boceprevir and in 3% of controls. Erythropoietin was prescribed in 38% of patients on triple therapy and in 21% of controls. The rate of sustained virological response 12 weeks after completion of therapy (SVR12) was 61% versus 27%, respectively. Figure2 records the proportion of patients with undetectable HCV-RNA in the two study arms at different time points. Although all patients were on antiretroviral therapy (mostly HIV protease inhibitors), a similar proportion of patients on boceprevir (3/64) and controls (4/34) experienced HIV-RNA rebounds during hepatitis C therapy.


Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.

Lafeuillade A, Soriano V, Suzan-Monti M, Stevenson M, Izopet J, Stellbrink HJ - AIDS Res Ther (2012)

Treatment of chronic hepatitis C withBoceprevir in HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin, SVR12: sustained virological response at 12 weeks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472320&req=5

Figure 2: Treatment of chronic hepatitis C withBoceprevir in HIV/HCV coinfected patients. P: pegylated interferon, R: ribavirin, SVR12: sustained virological response at 12 weeks.
Mentions: The results so far available with boceprevir and telaprevir in HIV/HCV-coinfected patients were deeply discussed at ISHEID [41]. In the phase 2 boceprevir study, a total of 98 HCV genotype 1 patients were randomized to receive either triple therapy or standard of care (peginterferon-ribavirin) for one year. Two thirds of patients were infected with HCV subtype 1a. Seven patients experienced viral breakthrough during therapy, 3/64 in the boceprevir arm and 4/34 in the control arm. Severe anemia developed in 5% of patients assigned to boceprevir and in 3% of controls. Erythropoietin was prescribed in 38% of patients on triple therapy and in 21% of controls. The rate of sustained virological response 12 weeks after completion of therapy (SVR12) was 61% versus 27%, respectively. Figure2 records the proportion of patients with undetectable HCV-RNA in the two study arms at different time points. Although all patients were on antiretroviral therapy (mostly HIV protease inhibitors), a similar proportion of patients on boceprevir (3/64) and controls (4/34) experienced HIV-RNA rebounds during hepatitis C therapy.

Bottom Line: However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted.Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual.The main 2012 ISHEID theme was, hence "searching for an HIV cure".

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Infectious Diseases, General Hospital, Toulon, France. alain.lafeuillade@ch-toulon.fr.

ABSTRACT
The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence "searching for an HIV cure". In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.

No MeSH data available.


Related in: MedlinePlus